ASND Valuation

Ascendis Pharma A/S

Add to Watchlist

Advanced Chart

197.740

-1.54(-0.773%)1D

ASND Relative Valuation

ASND's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ASND is overvalued; if below, it's undervalued.

Historical Valuation

Ascendis Pharma A/S (ASND) is now in the Fair zone, suggesting that its current forward PS ratio of 170.99 is considered Fairly compared with the five-year average of -4.96. The fair price of Ascendis Pharma A/S (ASND) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：197.74

Fair

171.45

Trailing

Forward

749.55

EV/EBITDA

Ascendis Pharma A/S. (ASND) has a current EV/EBITDA of 749.55. The 5-year average EV/EBITDA is -9.84. The thresholds are as follows: Strongly Undervalued below -128.09, Undervalued between -128.09 and -68.97, Fairly Valued between 49.29 and -68.97, Overvalued between 49.29 and 108.42, and Strongly Overvalued above 108.42. The current Forward EV/EBITDA of 749.55 falls within the Strongly Overvalued range.

89.78

EV/EBIT

Ascendis Pharma A/S. (ASND) has a current EV/EBIT of 89.78. The 5-year average EV/EBIT is -13.74. The thresholds are as follows: Strongly Undervalued below -76.15, Undervalued between -76.15 and -44.94, Fairly Valued between 17.46 and -44.94, Overvalued between 17.46 and 48.66, and Strongly Overvalued above 48.66. The current Forward EV/EBIT of 89.78 falls within the Strongly Overvalued range.

170.99

Ascendis Pharma A/S. (ASND) has a current PS of 170.99. The 5-year average PS is 129.20. The thresholds are as follows: Strongly Undervalued below -324.47, Undervalued between -324.47 and -97.64, Fairly Valued between 356.03 and -97.64, Overvalued between 356.03 and 582.87, and Strongly Overvalued above 582.87. The current Forward PS of 170.99 falls within the Historic Trend Line -Fairly Valued range.

43.00

P/OCF

Ascendis Pharma A/S. (ASND) has a current P/OCF of 43.00. The 5-year average P/OCF is 8.23. The thresholds are as follows: Strongly Undervalued below -1601.08, Undervalued between -1601.08 and -796.42, Fairly Valued between 812.88 and -796.42, Overvalued between 812.88 and 1617.54, and Strongly Overvalued above 1617.54. The current Forward P/OCF of 43.00 falls within the Historic Trend Line -Fairly Valued range.

35.99

P/FCF

Ascendis Pharma A/S. (ASND) has a current P/FCF of 35.99. The 5-year average P/FCF is -19.16. The thresholds are as follows: Strongly Undervalued below -56.52, Undervalued between -56.52 and -37.84, Fairly Valued between -0.48 and -37.84, Overvalued between -0.48 and 18.19, and Strongly Overvalued above 18.19. The current Forward P/FCF of 35.99 falls within the Strongly Overvalued range.

Ascendis Pharma A/S (ASND) has a current Price-to-Book (P/B) ratio of -55.20. Compared to its 3-year average P/B ratio of -24.97 , the current P/B ratio is approximately 121.04% higher. Relative to its 5-year average P/B ratio of -11.61, the current P/B ratio is about 375.33% higher. Ascendis Pharma A/S (ASND) has a Forward Free Cash Flow (FCF) yield of approximately -1.64%. Compared to its 3-year average FCF yield of -6.54%, the current FCF yield is approximately -75.00% lower. Relative to its 5-year average FCF yield of -6.58% , the current FCF yield is about -75.16% lower.

-55.20

P/B

Median3y

-24.97

Median5y

-11.61

-1.64

FCF Yield

Median3y

-6.54

Median5y

-6.58

Competitors Valuation Multiple

The average P/S ratio for ASND's competitors is 134.21, providing a benchmark for relative valuation. Ascendis Pharma A/S Corp (ASND) exhibits a P/S ratio of 170.99, which is 27.40% above the industry average. Given its robust revenue growth of 339.04%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Ionis Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

489.26

362.03%

11.11B

Performance Decomposition

Market capitalization of ASND increased by 45.31% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 36.00M to 158.05M.

The secondary factor is the Margin Expansion, contributed -91.91%to the performance.

Overall, the performance of ASND in the past 1 year is driven by Revenue Growth. Which is more sustainable.

339.04%

36.00M → 158.05M

Revenue Growth

-91.91%

-303.85 → -24.58

Margin Expansion

-201.82%

36.79 → -37.46

P/E Change

45.31%